2509: Qyuns Therapeutics Co., Ltd. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Qyuns Therapeutics Co., Ltd.

HKG:2509

SummaryFactSheetFinancial
Price
HK$13.99
Loss Chance
46.1%
3.64JITTA SCORE
45.02%Under Jitta Line
Jitta Ranking
Biotechnology
4 / 61
Health Care
27 / 234
Hong Kong
?
199 / 2,522
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Essex Bio-Technology Limited
HKG:1061
6.96
HK$2.64
63.12%
3SBio
HKG:1530
7.67
HK$16.09
77.20%
Everest Medicines Limited
HKG:1952
4.59
HK$25.50
7.28%
HBM Holdings Limited
HKG:2142
5.46
HK$10.51
10.15%
Mabpharm Private Limited
HKG:2181
n/a
HK$n/a
n/a
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (78)
Financial Strength (45)
Return to Shareholders (22)
Competitive Advantage (45)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
3.64
45.02%
3.04
203.42%
3.82
189.55%
Biotechnology
6.96
63.12%
7.67
77.20%
4.59
7.28%
COMPANY DESCRIPTION
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn’s disease. The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
www.qyuns.net
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.